|

Trastuzumab Deruxtecan (T-DXd) monotherapy Clinical Trials

1 actively recruiting trial

Also known as: DS-8201a

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Center Hospital East1

Indications

  • Gastroesophageal Junction Adenocarcinoma1
  • Gastric Adenocarcinoma1
  • Cancer1

Other1 trial

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.